CD274 and non-small cell lung carcinoma: In January 2021, tiragolumab (anti-TIGIT) combined with atezolizumab was approved by FDA for the treatment of metastatic non-small cell lung cancer patients with PD-L1 but without EGFR/ALK genome abnormalities.